153 related articles for article (PubMed ID: 30452692)
21. Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.
Honda T; Hishizawa M; Kataoka TR; Ohmori K; Takaori-Kondo A; Miyachi Y; Kabashima K
Acta Derm Venereol; 2015 May; 95(5):606-7. PubMed ID: 25424342
[No Abstract] [Full Text] [Related]
22. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
Mukai M; Maeda H; Narushima K; Mould DR; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
[TBL] [Abstract][Full Text] [Related]
23. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
24. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
[TBL] [Abstract][Full Text] [Related]
25. [Adult T-cell leukemia-lymphoma complicated by Takotsubo cardiomyopathy and HTLV-1-associated myelopathy after treatment with the anti-CCR4 antibody mogamulizumab].
Yamanaka S; Nakayama K; Tamai H; Sakamaki M; Inokuchi K
Rinsho Ketsueki; 2017; 58(4):309-314. PubMed ID: 28484158
[TBL] [Abstract][Full Text] [Related]
26. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
Ishitsuka K; Yurimoto S; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
Eur J Haematol; 2019 May; 102(5):407-415. PubMed ID: 30740787
[TBL] [Abstract][Full Text] [Related]
27. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
Mukai M; Mould D; Maeda H; Narushima K; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous Adverse Reaction to Mogamulizumab May Indicate Favourable Prognosis in Adult T-cell Leukaemia-lymphoma.
Yonekura K; Tokunaga M; Kawakami N; Takeda K; Kanzaki T; Nakano N; Kubota A; Takeuchi S; Takatsuka Y; Seto M; Utsunomiya A
Acta Derm Venereol; 2016 Nov; 96(7):1000-1002. PubMed ID: 27025906
[No Abstract] [Full Text] [Related]
29. CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
Sakamoto Y; Ishida T; Masaki A; Murase T; Ohtsuka E; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
Hematol Oncol; 2022 Dec; 40(5):876-884. PubMed ID: 36043457
[TBL] [Abstract][Full Text] [Related]
30. Appropriate radiation dose for symptomatic relief and local control in patients with adult T cell leukemia/lymphoma.
Maemoto H; Ariga T; Nakachi S; Toita T; Hashimoto S; Heianna J; Shiina H; Kusada T; Makino W; Kakinohana Y; Miyagi T; Yamamoto Y; Morishima S; Masuzaki H; Murayama S
J Radiat Res; 2019 Jan; 60(1):98-108. PubMed ID: 30124892
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
[TBL] [Abstract][Full Text] [Related]
32. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J
Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
[TBL] [Abstract][Full Text] [Related]
33. Depletion of regulatory FoxP3
Amakata M; Teraki Y
Int J Dermatol; 2019 Dec; 58(12):e247-e249. PubMed ID: 31334834
[No Abstract] [Full Text] [Related]
34. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.
Simone CB; Morris JC; Stewart DM; Urquhart NE; Janik JE; Kreitman RJ; Lita E; Conlon K; Wharfe G; Waldmann TA; Kaushal A
Blood; 2012 Aug; 120(9):1816-9. PubMed ID: 22730536
[TBL] [Abstract][Full Text] [Related]
35. Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab.
Tanba K; Uoshima N; Uchiyama H; Kawata E; Isa R; Yamaguchi J; Tsutsumi Y; Akaogi T; Kobayashi Y; Katsura K; Kuroda J; Taniwaki M
Ann Hematol; 2016 Mar; 95(4):661-2. PubMed ID: 26754634
[No Abstract] [Full Text] [Related]
36. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
[TBL] [Abstract][Full Text] [Related]
37. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
38. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
Duvic M; Pinter-Brown LC; Foss FM; Sokol L; Jorgensen JL; Challagundla P; Dwyer KM; Zhang X; Kurman MR; Ballerini R; Liu L; Kim YH
Blood; 2015 Mar; 125(12):1883-9. PubMed ID: 25605368
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
Nosaka K; Kusumoto S; Nakano N; Choi I; Yoshimitsu M; Imaizumi Y; Hidaka M; Sasaki H; Makiyama J; Ohtsuka E; Jo T; Ogata M; Ito A; Yonekura K; Tatetsu H; Kato T; Kawakita T; Suehiro Y; Ishitsuka K; Iida S; Matsutani T; Utsunomiya A; Ueda R; Ishida T
Br J Haematol; 2022 Feb; 196(3):629-638. PubMed ID: 34632569
[TBL] [Abstract][Full Text] [Related]
40. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
